Zentalis Pharmaceuticals (ZNTL) director granted 57,100 restricted stock units
Rhea-AI Filing Summary
Walker Luke Nathaniel reported acquisition or exercise transactions in this Form 4 filing.
Zentalis Pharmaceuticals director Luke Nathaniel Walker received an equity award of 57,100 shares of common stock in the form of restricted stock units. These units were granted at no cash cost and increase his direct holdings to 201,384 shares of common stock.
The restricted stock units each represent a contingent right to receive one share of common stock. They will vest on the earlier of June 16, 2027 or the next annual meeting of stockholders, provided Walker continues to serve on the board through the vesting date. This is a compensation-related grant rather than an open-market purchase.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Walker Luke Nathaniel
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 57,100 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 201,384 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
RSU grant size: 57,100 shares
Holdings after grant: 201,384 shares
Vesting date: June 16, 2027
3 metrics
RSU grant size
57,100 shares
Restricted stock units granted to director on June 16, 2026
Holdings after grant
201,384 shares
Total common stock held directly following the transaction
Vesting date
June 16, 2027
Earlier of this date or next annual stockholder meeting, subject to continued service
Key Terms
restricted stock units, Non-Employee Director Compensation Program, contingent right to receive one share of common stock, vesting date
4 terms
restricted stock units financial
"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Non-Employee Director Compensation Program financial
"restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program"
vesting date financial
"subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Luke Nathaniel Walker acquire in Zentalis Pharmaceuticals (ZNTL)?
Luke Nathaniel Walker received 57,100 restricted stock units in Zentalis Pharmaceuticals as a compensation grant. Each unit represents a contingent right to one share of common stock, rather than a cash transaction or open-market share purchase.
When do Luke Nathaniel Walker’s new Zentalis (ZNTL) restricted stock units vest?
The restricted stock units vest on the first to occur of June 16, 2027 or the next annual meeting of Zentalis stockholders. Vesting is conditioned on Walker’s continued service on the company’s board of directors through the applicable vesting date.
Is Luke Nathaniel Walker’s Zentalis (ZNTL) transaction a market buy or compensation grant?
The transaction is a compensation-related grant, not an open-market purchase. Code A on the Form 4 reflects a grant or award of 57,100 restricted stock units under Zentalis’ Non-Employee Director Compensation Program at no cash cost per share.
What is the nature of the restricted stock units granted to Luke Nathaniel Walker at Zentalis (ZNTL)?
Each restricted stock unit represents a contingent right to receive one Zentalis common share. The award was granted under the Non-Employee Director Compensation Program and will only convert into actual shares if vesting conditions tied to continued board service are met.